/ RIVERVEST NEWS

RiverVest is a leading venture capital firm building life science companies
to address significant unmet needs of patients and deliver consistently strong returns to investors.

/ PORTFOLIO COMPANY NEWS

SeQure Dx

Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers – 1/23/2024

Spruce Biosciences

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia – 1/22/2024

Wugen, Inc.

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting – 12/11/2023

VentureMed Group, Inc.

VentureMed Receives Transitional Pass-through Payment (TPT) for FLEX Vessel Prep™ System – 11/8/2023

Spruce Biosciences

Spruce Biosciences Completes Target Enrollment of Cahmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia – 10/18/2023

Reneo Pharmaceuticals

Reneo Pharmaceuticals Announces Last Patient Last visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) – 10/9/2023

Avalyn Pharma

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies – 9/27/2023

Mirum Pharmaceuticals

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics – 9/5/2023

Wugen, Inc.

Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refactory (R/R) Acute Myeloid Leukemia (AML) – 8/15/2023

Xilio Therapeutics

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results 8/14/2023

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results 8/10/2023

Allakos, Inc.

Allakos provides Business Update and Reports Second Quarter 2023 Financial Results 8/9/2023

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update 8/3/2023

Mirum Pharmaceuticals

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics 7/17/2023

Biolinq Incorporated

Biolinq and Taisho Pharmaceutical Announce Strategic Collaboration and Exclusive License Agreement in Japan 6/20/2023

Wugen, Inc.

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at European Hematology Association (EHA) 2023 Congress  6/9/2023

Bluejay Therapeutics

Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment  6/1/2023

Xilio Therapeutics

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors 5/25/2023

OncoResponse

OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy 5/18/2023

Spruce Biosciences

Reports First Quarter 2023 Financial Results and Provides Corporate Updates – 5/15/2023

Reneo Pharmaceuticals

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results 5/11/2023

Wugen, Inc.

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors – 5/10/2023

Allakos, Inc.

Provides Business Update and Reports First Quarter 2023 Financial Results – 5/9/2023

Xilio Therapeutics

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results – 5/9/2023

Mirum Pharmaceuticals

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update – 5/4/2023

Reneo Pharmaceuticals

Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock – 5/3/2023

Avalyn Pharma

Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis– 4/11/2023

Mirum Pharmaceuticals Inc.

Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors– 4/6/2023

Avalyn Pharma Inc.

Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile – 3/23/2023

Wugen, Inc. Announces CEO Transition Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer 3/21/2023

Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies – 3/14/2023

Mirum Pharmaceuticals Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older- 3/14/2023

Allakos, Inc.

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results – 3/6/2023

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis – 2/14/2023

Spruce Biosciences Announces $53.6 Million Private Placement Financing – 2/9/2023

Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) – 1/31/2023

Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial – 1/26/2023

Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG – 1/9/2023

Spruce Biosciences and Karen Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan – 1/5/2023

Mirum Pharmaceuticals LIV MARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older – 12/13/2022

Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D – 12/1/2022
logo-rivervest

St. Louis

101 S. Hanley Road, Suite 1850
St. Louis, MO 63105
Phone: (314) 726.6700

San Diego

10996 Torreyana Road, Suite 280
San Diego, CA 92121
Phone: (314) 726.6700

Cleveland

11000 Cedar Avenue
Cleveland, OH 44106
Phone: (216) 658.3982
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation. Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2024 RiverVest® All Rights Reserved. | Privacy Policy

Subscribe to our newsletter

Rivervest Contact